Myelodysplastic Syndrome (MDS) Drugs Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The myelodysplastic syndrome (MDS) drugs market size has grown strongly in recent years. It will grow from $3.47 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.

The myelodysplastic syndrome (MDS) drugs market size is expected to see strong growth in the next few years. It will grow to $5.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.

The growing exposure to cancer treatments, such as chemotherapy and radiation, is expected to stimulate the expansion of the myelodysplastic syndrome (MDS) drug market in the coming years. Chemotherapy involves the use of medications to eliminate cancer cells, while radiation therapy employs high doses of radiation to target cancer cells and reduce tumor sizes. Both chemotherapy drugs and radiation treatments can negatively affect the bone marrow's stem cells, which play a crucial role in generating new blood cells. This disruption in normal cell production can lead to the development of MDS. Myelodysplastic syndrome (MDS) drugs offer various benefits in managing and treating MDS, a group of disorders characterized by abnormal blood cell production in the bone marrow. For instance, the European Society of Radiation Oncology (ESTRO) estimates that there will be a 16% increase in the number of radiotherapy treatment courses by 2025 based on projected cancer distributions. Consequently, the rising exposure to cancer treatments, including chemotherapy and radiation, is a driving force behind the growth of the myelodysplastic syndrome (MDS) drugs market.

The surge in myeloid leukemia cases is projected to advance the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia is a type of cancer originating in the bone marrow, impacting the cells responsible for generating various blood cell types. Myelodysplastic syndrome (MDS) drugs aim to enhance bone marrow function by addressing the root causes of leukemia, thereby reducing the risk of complications associated with low blood cell counts, decreasing the necessity for chemotherapy and transplants, and ultimately improving survival rates for individuals with myelodysplastic syndrome (MDS). For example, the American Cancer Society estimates that there will be around 20,380 cases and 11,310 deaths in adults from acute myeloid leukemia (AML) in 2023. Consequently, the increasing incidence of myeloid leukemia is a key driver behind the myelodysplastic syndrome (MDS) drug market's growth.

Leading companies in the myelodysplastic syndrome (MDS) drugs market are concentrating on the development of new products, such as targeted therapies, to enhance patient outcomes, address specific customer needs, and integrate into the medical ecosystem. Targeted therapy for MDS involves drugs that precisely address genetic mutations or molecular irregularities in cancer cells, with the goal of improving outcomes by focusing on abnormal cells while reducing harm to healthy tissue. For example, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for treating adult patients with relapsed or refractory (R/R) MDS with an isocitrate dehydrogenase-1 (IDH1) mutation. This approval was based on the effectiveness of Tibsovo in an open-label, single-arm, multicenter study involving 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

In April 2022, GlaxoSmithKline plc, a focused biopharmaceutical company, acquired Sierra Oncology, Inc. for $1.9 billion. This acquisition supports GSK's broader strategy to strengthen its portfolio of specialty medicines and vaccines, with a focus on oncology and addressing unmet needs within the rare disease patient population. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company specializing in targeted therapies for treating rare cancers and myelodysplastic syndrome (MDS).

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the myelodysplastic syndrome (MDS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) drugs market consists of sales of vidaza (azacitidine), dacogen (decitabine) and reblozyl (luspatercept-aamt). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Myelodysplastic syndrome (MDS) drugs are pharmaceuticals utilized in the treatment of myelodysplastic syndrome, a group of bone marrow disorders characterized by insufficient production of healthy blood cells. These drugs operate by facilitating the restoration of normal gene function in bone marrow cells, leading to increased red blood cell production.

The primary categories of drugs used for myelodysplastic syndrome (MDS) treatment include chemotherapy and immunomodulatory drugs. Chemotherapy is a cancer treatment approach that employs anti-cancer medications to eliminate cancerous cells. These drugs can be administered via oral or parenteral routes to manage conditions such as refractory cytopenia with multilineage dysplasia, refractory anemia, and refractory anemia with ringed sideroblasts. Various healthcare settings, including hospitals, clinics, and ambulatory surgical centers, are involved in the distribution and administration of these drugs.

The myelodysplastic syndrome (MDS) drugs market research report is one of a series of new reports that provides myelodysplastic syndrome (MDS) drugs market statistics, including myelodysplastic syndrome (MDS) drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome (MDS) drugs market share, detailed myelodysplastic syndrome (MDS) drugs market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome (MDS) drugs industry. This myelodysplastic syndrome (MDS) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.